Dietary Modification Clinical Trial
— PREMIUMOfficial title:
The Impact of a Powdered Meal Replacement on Metabolism and Gut Microbiota: a 12-week Study in Individuals With Excessive Body Weight
Verified date | December 2023 |
Source | University of Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will investigate the impact of a 12-week powdered meal replacement on inflammatory, metabolic, and hormonal markers of obesity-associated conditions and to correlate this response to compositional shifts within the gut microbiota. Moreover, resting energy expenditure, body composition, appetite sensations and soy metabolomics will be explored. This study will be a randomized, parallel group, clinical trial of a 12-week nutritional intervention. A sample size of n=88 participants will be randomly allocated into one of the following groups: - Control group (CON): Participants will be asked to maintain their usual dietary intake over 12 weeks. Their usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat). - Powdered Meal Replacement group (PMR): Participants will be asked to maintain their usual dietary intake and consume a powdered meal replacement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the meal replacement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The following variables will be analyzed: - Interleukin (IL)-6. - Gut microbiota diversity and composition, specifically taxa that have been associated with health benefits, obesity, and weight loss. - Systemic inflammatory biomarkers (high-sensitivity C-reactive protein, IL-8, IL-10 and tumor necrosis factor-α); - Metabolic blood markers (glucose, insulin, lipid panel, peptide tyrosine-tyrosine, glucagon-like peptide-1, ghrelin, adiponectin, leptin, free glycerol, free fatty acids, and thyroid stimulating hormone) - Resting energy expenditure; - Body composition; - Appetite sensations (hunger, satiety, fullness, and prospective food consumption); - Soy polyphenols' metabolomics. - Gene expression and genetic polymorphisms. At baseline and after 6 and 12 weeks, individuals will attend our Human Nutrition Research Unit where all assessments will take place. In order to assess participants' adherence and follow-up, dietary intake, body weight and appetite sensations (only for participants assigned to the PMR group) will be assessed weekly during the 12-week intervention period. Additionally, participants will be contacted by phone weekly and reminded to maintain their journal/log.
Status | Completed |
Enrollment | 88 |
Est. completion date | December 8, 2023 |
Est. primary completion date | December 8, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Non-smoker; - Female/Male; - Aged 18 to 50 years; - Body mass index (BMI) between 25 and 37 kg/m²; - Weight stable (< ± 5 kg over past 6 months); - Fat mass =20% for men and =25% for women; - Maintaining current levels of physical activity throughout the study. - Female participants must verify use of acceptable, effective birth control methods (total abstinence, hormonal birth control [oral, injectable, transdermal, intravaginal], intrauterine devices, confirmed successful vasectomy or partner, or condoms). Exclusion Criteria: - Diagnosis of chronic diseases or acute infections; - Taking any medication that may alter inflammation, energy metabolism, body weight and composition, gut microbiota and hormone levels; investigators should always be informed if there are any changes in medications or Natural health product use; - Taking pre- and probiotics (e.g. supplements); - Use of antibiotics in the past two months; - Use of thyroid replacement therapy; - Use of nutritional supplements in the past four weeks (multivitamin and vitamin D3 are permitted to be used during the course of the study); - Allergy to any ingredient (including non-medicinal ingredients) in investigational product; - Lactose, gluten and/or soy allergic/intolerant; - Follow a vegetarian, vegan or any restrictive dietary pattern; - Pregnant or lactating; - Perform over three hours of vigorous physical activity per week; - A nuclear medicine scan or injection of an X-ray dye in the past week; - A barium test/exam in the last two weeks; - Suffer from claustrophobia; - Inability to comprehend and complete the required questionnaires. |
Country | Name | City | State |
---|---|---|---|
Canada | Human Nutrition Research Unit | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Almased Wellness GmbH |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | High-sensitivity C-reactive protein. | Changes in blood high-sensitivity C-reactive protein will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Interleukin 8. | Changes in interleukin 8 will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Interleukin 10. | Changes in interleukin 10 will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Tumor necrosis factor-a. | Changes in tumor necrosis factor-a will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Adiponectin. | Changes in adiponectin will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Blood glucose. | Changes in blood glucose will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Insulin. | Changes in insulin will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Lipid panel. | Changes in lipid panel (i.e. total cholesterol, LDL, HDL and triglycerides) will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Peptide tyrosine-tyrosine. | Changes in peptide tyrosine-tyrosine will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Glucagon-like peptide 1. | Changes in glucagon-like peptide-1 will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Ghrelin. | Changes in ghrelin will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Leptin. | Changes in leptin will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Free glycerol. | Changes free glycerol will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Free fatty acids. | Changes in free fatty acids will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Thyroid stimulating hormone. | Changes in thyroid stimulating hormone will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Resting energy expenditure. | Changes in resting energy expenditure will be assessed at baseline, middle and end of the 12-week dietary intervention period using a whole body calorimetry unit. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Body composition. | Changes in fat mass, lean soft tissue and bone mineral content will be assessed at baseline, middle and end of the 12-week dietary intervention period using dual-energy X-ray absorptiometry. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Appetite sensations. | Changes in hunger, satiety, fullness, and prospective food consumption will be assessed weekly using a 100 mm visual analogue scale. | Once per week during the intervention period (12 weeks). | |
Other | Soy polyphenols' metabolomics. | Soy polyphenols' metabolomics will be assessed on participants assigned to the 12-week dietary intervention periodPowdered Meal Replacement group at baseline, middle and end of the 12-week dietary intervention period using blood and urine samples. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Other | Gene expression | Changes in gene expression will be assessed at baseline and at the end of the 12-week dietary intervention period | At baseline (week 1) and end (week 12) of the intervention period (12 weeks). | |
Other | Genetic polymorphisms | Genetic polymorphisms will be identified at baseline | At baseline (week 1) | |
Primary | Interleukin-6. | Changes in blood interleukin-6 will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). | |
Secondary | Gut microbiota diversity and composition. | Changes in gut microbiome diversity and composition (specifically taxa that have been associated with health benefits, obesity and weight loss) will be assessed at baseline, middle and end of the 12-week dietary intervention period. | At baseline (week 1), middle (week 6) and end (week 12) of the intervention period (12 weeks). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Completed |
NCT03048487 -
Protein Consumption in Critically Ill Patients
|
||
Completed |
NCT03024983 -
Pasta and Other Durum Wheat-based Products: Effects on Post-prandial Glucose Metabolism
|
N/A | |
Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
Recruiting |
NCT02848807 -
Chemotherapy-related Toxicity, Nutritional Status and Quality of Life
|
N/A | |
Completed |
NCT02416284 -
Compliance to the Norwegian Food-Based Dietary Guidelines in Young Females
|
N/A | |
Completed |
NCT01559896 -
Egg Protein Hydrolysate and Vascular Function
|
N/A | |
Terminated |
NCT01329172 -
Nasal Mucin Oral Supplementation Treatment Respiratory Inflammation Using PUFA in Cystic Fibrosis (CF) Patients
|
N/A | |
Completed |
NCT03698929 -
Effect of Dietary Cholesterol on Plasma Lipids
|
N/A | |
Completed |
NCT03942822 -
Chia Supplementation and Non Alcoholic Fatty Liver Disease
|
N/A | |
Completed |
NCT03319836 -
Meeting Protein Targets in Critically Ill Patients
|
||
Completed |
NCT02940197 -
Comparison of Two Calorie Restricted MediterrAsian Diet on Weight Loss in FTO rs9939609 Overweight Carriers
|
N/A | |
Completed |
NCT02811276 -
The Impact of a High Protein Diet on Substrate Oxidation and Energy Metabolism
|
N/A | |
Completed |
NCT02582554 -
Efficacy of Nutrition Risk Screening With NutriSTEP® in Toddlers and Preschoolers
|
N/A | |
Completed |
NCT02574052 -
Medical College Students' Responds to Menu Labeling
|
Phase 3 | |
Completed |
NCT02274220 -
Feeding Study - Effects Post-cardiac Surgery
|
N/A | |
Completed |
NCT02898844 -
Randomized Controlled Experiment of Dieting in Pairs
|
N/A |